In RAS-mutant tumours, MEK inhibition as monotherapy has failed to demonstrate meaningful benefits largely due to the induction of feedback loops similar to those when RAF inhibitors are use in this setting[48]. The gene discussed is MAP2K7; the disease is neoplasm.